Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

138.55
-1.2200-0.87%
Post-market: 138.590.0400+0.03%19:44 EDT
Volume:3.43M
Turnover:475.85M
Market Cap:171.90B
PE:20.44
High:140.27
Open:138.61
Low:137.75
Close:139.77
52wk High:157.29
52wk Low:93.37
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.72
T/O Rate:0.28%
Dividend:3.16
Dividend Rate:2.28%
EPS(TTM):6.78
EPS(LYR):6.78
ROE:40.66%
ROA:12.52%
PB:7.57
PE(LYR):20.44

Loading ...

Gilead Sciences (GILD) Receives a Buy from Scotiabank

TIPRANKS
·
Feb 24

Citi Reaffirms Their Buy Rating on Gilead Sciences (GILD)

TIPRANKS
·
Feb 24

CORRECTED-Belgium's Galapagos 2025 net revenue surges, driven by Gilead collaboration

Reuters
·
Feb 24

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Feb 24

Arcellx Stock (ACLX) Rockets on a Massive Deal with Gilead Sciences (GILD)

TIPRANKS
·
Feb 24

Arcellx downgraded to Hold from Buy at Needham

TIPRANKS
·
Feb 23

Arcellx downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
Feb 23

Gilead Sciences Shares Down 0.8%

THOMSON REUTERS
·
Feb 23

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Renewed Trade Doubts

MT Newswires Live
·
Feb 23

Arcellx downgraded to Equal Weight from Overweight at Wells Fargo

TIPRANKS
·
Feb 23

Top Premarket Gainers

MT Newswires Live
·
Feb 23

Gilead Sciences to Acquire Arcellx in Major Cell-Therapy Deal

TIPRANKS
·
Feb 23

Gilead - IF Deal Is Terminated Under Certain Circumstances, Arcellx to Pay Gilead Termination Fee of $260 Mln

THOMSON REUTERS
·
Feb 23

BRIEF-Gilead Sciences To Acquire Arcellx To Maximize Long-Term Potential Of Anito-Cel

Reuters
·
Feb 23

Deals of the day-Mergers and acquisitions

Reuters
·
Feb 23

Gilead to Acquire Cancer Therapy Developer Arcellx for up to $7.8 Billion

Reuters
·
Feb 23

Gilead to acquire Arcellx for $115 per share in cash at closing, or $7.8B

TIPRANKS
·
Feb 23

Gilead Sciences Shares Down 1.3% Premarket

THOMSON REUTERS
·
Feb 23

Gilead - to Buy Arcellx for $115 per Share in Cash

THOMSON REUTERS
·
Feb 23

Gilead - Deal Expected to Be Accretive to EPS in 2028 and Thereafter

THOMSON REUTERS
·
Feb 23